<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 11">
<meta name=Originator content="Microsoft Word 11">
<link rel=File-List href="Page2_files/filelist.xml">
<link rel=Edit-Time-Data href="Page2_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>jennifer mcdowall</o:LastAuthor>
  <o:Revision>4</o:Revision>
  <o:TotalTime>212</o:TotalTime>
  <o:Created>2003-10-02T08:48:00Z</o:Created>
  <o:LastSaved>2008-01-18T10:18:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>772</o:Words>
  <o:Characters>4401</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>36</o:Lines>
  <o:Paragraphs>10</o:Paragraphs>
  <o:CharactersWithSpaces>5163</o:CharactersWithSpaces>
  <o:Version>11.8132</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" LatentStyleCount="156">
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=blue style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/index.html"
title="To InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:113.25pt;
 height:36.75pt'>
 <v:imagedata src="Page2_files/image001.jpg" o:title="InterPro_logo"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=151 height=49
src="Page2_files/image001.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy'>Trypsin and Chymotrypsin<o:p></o:p></span></h1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<h1><span style='color:navy'>Pancreatitis, when control fails<o:p></o:p></span></h1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Any
disturbance of the balance between proteolytic enzymes and their inhibitors, or
of the activation process, can result in pancreatits, where premature,
intracellular activation of zymogens cause the autodigestion of the pancreas.<span
style='mso-spacerun:yes'>  </span>During pancreatits, anionic trypsinogen
becomes the predominant isoforms secreted from the pancreas, and there is an
increased level of zymogen in serum.<span style='mso-spacerun:yes'> 
</span>Anionic trypsinogen exhibits increased autocatalytic degradation over
the cationic isoforms.<span style='mso-spacerun:yes'>  </span>Pancreatitis can
occur as a hereditary, autodominant condition, as part of the pathogenesis of
cystic fibrosis or as a result of alcohol toxicity.<span
style='mso-spacerun:yes'>  </span></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Hereditary
pancreatitis results in recurrent attacks of acute pancreatitis, progressing to
chronic pancreatitis at a young age.<span style='mso-spacerun:yes'> 
</span>Mutations in the cationinc trypsinogen I gene have been characterised
from several patients.<span style='mso-spacerun:yes'>  </span>One of these
mutations was shown to alter a trypsin recognition site, preventing the
deactivation of trypsin within the pancreas, resulting in autodigestion.<span
style='mso-spacerun:yes'>  </span>Hereditary pancreatitis can also result in
patients with mutations in the trypsin/trypsinogen inhibitor SPINK1, which
leads to the inappropriate activation of pancreatic zymogens.<span
style='mso-spacerun:yes'>  </span>SPINK1 mutations appear to cause a more rapid
progression of chronic pancreatitis than cationic trypsinogen mutations. </p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Cystic
fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene.<span
style='mso-spacerun:yes'>  </span>Patients with CF often suffer from recurrent
pancreatitis.<span style='mso-spacerun:yes'>  </span>CF is thought ot interfere
with the negative feedback loop that helps regulate pancreatic zymogen
secretion.<span style='mso-spacerun:yes'>  </span>A high concentration of
protease in the duodenum inhibits cholecystokinin (CCK) secretion, thereby
reducing pancreatic secretion of zymogens; a high concentration of inhibitors
induces pancreatic zymogen secretion through CCK.<span
style='mso-spacerun:yes'>  </span>In CF, it has been suggested that obstruction
to pancreatic zymogen secretion could induce CCK release, which in turn
stimulates pancreatic zymogen production.<span style='mso-spacerun:yes'> 
</span>The blockage of zymogen secretion together with its continued synthesis
could result in the built-up of digestive enzymes within lysosomes, which could
then rupture into the cytoplasm.<span style='mso-spacerun:yes'>  </span></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Chronic
alcohol consumption is known to increase the synthesis of several digestive
enzymes in the pancreas, including trypsinogen.<span style='mso-spacerun:yes'> 
</span>Progression to chronic pancreatitis can be rapid.<span
style='mso-spacerun:yes'>  </span>As fewer than 10% of alcoholics develop
chronic pancreatits, other genetic or environmental factors must be involved.</p>

<h1><span style='color:navy'>Trypsin, chymotrypsin and cancer<o:p></o:p></span></h1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Hereditary pancreatitis
carries a 40% risk of pancreatic cancer (5% risk for non-hereditary pancreatitis),
a very invasive cancer with high mortality rates.<span
style='mso-spacerun:yes'>  </span>Pancreatic inflammation promotes intensive
cell proliferation to regenerate the damaged pancreas, during which the
amplification of pathological changes in DNA can occur.<span
style='mso-spacerun:yes'>  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Elevated
levels of trypsin have been found in a variety of other tumours, such as
ovarian and colorectal carcinomas, where it may have a role in malignant tumour
formation or metastasis.<span style='mso-spacerun:yes'>  </span>Trypsins appear
to be necessary for cancer cells to invade normal tissue, and to enter the
bloodstream and lymphatic channels.<span style='mso-spacerun:yes'>  </span>A
critical step in cancer metastasis involves breaking down the extracellular
matrix surrounding the malignant tumour, which allows it to invade and spread.<span
style='mso-spacerun:yes'>  </span>Type I collagen degradation involves the action
of matrix metalloproteases (MMP-1, -8 and -13), which are activated by
MMP-3.<span style='mso-spacerun:yes'>  </span>Trypsin-2 can directly activate
all four pro-MMP enzymes, and can degrade type I collagen, acting as a potent
tumour-associated matrix serine protease.<span style='mso-spacerun:yes'> 
</span>The inhibitor TATI (tumour-associated trypsin inhibitor) can inhibit
trypsin activation of pro-MMPs and trypsin degradation of type I collagen.<span
style='mso-spacerun:yes'>  </span>Not surprisingly, TATI has been detected at
elevated levels in a variety of tumours and in the serum of cancer patients.
Trypsin has also been shown to activate a G protein-coupled receptor PAR-2
(protease-activated receptor-2) in both colon and pancreatic cancer cell lines,
where it appears to act as a potent mitogen <i>in vitro</i>, functioning as a
growth factor.<span style='mso-spacerun:yes'>  </span></p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Certain protease
inhibitors appear to be capable of suppressing carcinogenesis in a variety of
model systems, the most potent of which appear to inhibit chymotrypsin or
chymotrypsin-like proteases.<span style='mso-spacerun:yes'>  </span>Both
soybean-derived BBI (inhibits trypsin and chymotrypsin) and human
alpha1-antichymotrypsin are potent inhibitors of chymotrypsin, are highly
anti-inflammatory, and may be involved in defence of their respective
organisms.<span style='mso-spacerun:yes'>  </span>BBI was found to help
suppress a variety of tumours in different organisms, both <i>in vitro</i> and <i>in
vivo</i>.<span style='mso-spacerun:yes'>  </span>Extracts high in proteolytic
enzymes, especially trypsin, chymotrypsin and papain, have also been used in
cancer studies.<span style='mso-spacerun:yes'>  </span>Enzyme therapy appears
to be anti-inflammatory by its induction of protease inhibitors.</p>

<p class=MsoNormal style='text-indent:36.0pt'><o:p>&nbsp;</o:p></p>

<h1 align=center style='text-align:center'>Next:<span
style='mso-spacerun:yes'>  </span><a href="Page3.htm">What InterPro tells us</a></h1>

<h1 align=center style='text-align:center'>Previous:<span
style='mso-spacerun:yes'>  </span><a href="Page1.htm">Trypsin and chymotrypsin,
serine protease digestive enzymes</a></h1>

</div>

</body>

</html>
